title: Cabazitaxel in metastatic castration-resistant prostate cancer.
abstract: Metastatic castration-resistant prostate cancer (CRPC) has a poor prognosis and remains a significant therapeutic challenge. Prior to 2010, docetaxel chemotherapy was the only treatment shown to improve overall survival, symptom control and quality of life in patients with CRPC. Research efforts focused on overcoming chemoresistance to taxanes eventually led to the development of multiple novel anti-tumor agents, including cabazitaxel. Cabazitaxel has recently been shown to significantly improve overall survival compared with mitoxantrone in a large multicenter Phase III study. This article details the preclinical and clinical development of cabazitaxel and discusses the importance of this novel chemotherapy in CRPC. The authors also discuss the challenges now facing the future use of cabazitaxel in CRPC, including the determination of the optimal dose of cabazitaxel in patients with advanced CRPC, the ideal sequencing of cabazitaxel relative to other anti-tumor treatments, appropriate patient selection and novel strategies for the assessment of treatment response.
authors.affiliation: Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
authors.forename: Timothy A
authors.initials: TA
authors.lastname: Yap
authors.forename: Carmel J
authors.initials: CJ
authors.lastname: Pezaro
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001682:Biological Availability; D002986:Clinical Trials as Topic; D018450:Disease Progression; D060467:Disease Resistance / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009919:Orchiectomy / Q000009:adverse effects*; D011183:Postoperative Complications / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; C552428:cabazitaxel